Jovana Grbic explores a recent case on generic lidocaine patches

ACTION:  Infringement of U.S. Patent 5,827,529 (referred to as “529 Patent) by Noven Therapeutics/Noven Pharmaceuticals, makers of products such as the ADHD drug Daytrana, at a considerable harm to the transdermal drug delivery technology company Teikoku Seiyaku, Co., Ltd., holders of the patent, and Endo Pharmaceuticals, manufacturers of a 5% lidocaine patch that relieves pain associated with post-herpetic neuralgia utilizing technology covered by the patent.